Portage (PRTG) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Graphic logo of Portage (PRTG)

As reflected in the chart, the EV/EBITDA asset valuation for Portage Biotech Inc. (PRTG) stands at . The business relies on a virtual model, outsourcing synthesis and testing to third-party contractors to protect its patents. While speculative risks and a liquidity shortage constrain growth, a premier staff of scientists is retained through high salaries and research freedom to develop breakthrough tumor treatments.

PRTG Portage Biotech Inc: Enterprise Value to Operating Income Before Depreciation in the range 07/04/2022 - 11/11/2026

PRTG (portagebiotech.com): analytical breakdowns and indicator data

- stock price and consensus target price:
Stock Quotes Portage|PRTG - Fair Value Consensus
- market capitalization indicators:
Market Value Portage Biotech Corp|PRTG - Total Enterprise Value
- book value of equity indicators:
Net Assets per Single Share Portage Biotech|PRTG - Accounting Capitalization|Market Capitalization to Book Value Ratio portagebiotech.com|PRTG - Cumulative Company Assets
- debt and liquidity data:
Debt to Equity Portage Biotech Inc.|PRTG - Long-Term Liabilities to Capital|Short-Term Debt to Equity Portage Biotech|PRTG - Company Debts|Debt to Book Capitalization Ratio Portage Biotech Corp|PRTG - Long-Term Debt|Company Short-Term Debts Portage Biotech|Quick Liquidity Indicator portagebiotech.com
- business earnings and investment ratios data:
PRTG - Company Net Income|Future Profit Portage Biotech Inc.|PRTG - Company Value to Net Income|Projected Price to Earnings Portage Biotech Inc.|PRTG - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Portage Biotech Corp|PRTG - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Portage Biotech|PRTG - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months portagebiotech.com|PRTG - Earnings per share increase in current year|Earnings growth forecast for next year Portage Biotech Inc.
Summary company analytics:PRTG (Portage)
Original product of Portage Biotech

The EV/EBITDA multiple compares the total enterprise value of a business with its operating profit before depreciation, taxes, and interest, revealing the actual value of assets while accounting for debt load. For Portage Biotech Inc. (PRTG), which optimizes costs through ESG standards in immuno-oncology, the company's dynamic EV/EBITDA value of reflects its resource management efficiency. Analyzing this metric allows for the identification of the risk of overpaying for a business during periods of high debt dependency.

Competitor analysis

Incyte Corp. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation HCM|NUVB - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA dayonebio.com|Monopar Therapeutics Inc. (MNPR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation INBX|IMAB (I-Mab Biopharma Co., Ltd.) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Fennec (FENC)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Heron Therapeutics (HRTX)|NVCT - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Coherus BioSciences Inc. CHRS|Corbus Pharmaceuticals Holdings, Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CRDF - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA BeyondSpring Inc|BCAB: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple lixte.com LIXT|Enterprise Value to EBITDA Ratio CTXR|Company Value to EBITDA Cellectar Biosciences Inc CLRB|Enterprise Value to EBITDA Ratio BLRX (BioLineRx Corp)|CANF (Can-Fite) - Business Value to Operating Income Before Depreciation|Aprea Therapeutics, Inc. - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio KZIA (Kazia Therapeutics Ltd)|Silexion - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation NCNA (NuCana plc)|CMRX: EV/EBITDA Multiple|Company Value to EBITDA Cyclacel, Inc. (CYCC)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization G1 Therapeutics Inc.|KRON: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple KTRA|EV/EBITDA Multiple Oncternal Therapeutics Inc (ONCT)